<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0213-9111</journal-id>
<journal-title><![CDATA[Gaceta Sanitaria]]></journal-title>
<abbrev-journal-title><![CDATA[Gac Sanit]]></abbrev-journal-title>
<issn>0213-9111</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Salud Pública y Administración Sanitaria (SESPAS)]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0213-91112025000101401</article-id>
<article-id pub-id-type="doi">10.1016/j.gaceta.2024.102444</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study]]></article-title>
<article-title xml:lang="es"><![CDATA[Asociación de los agonistas del receptor del péptido similar al glucagón tipo 1 con la pancreatitis aguda y la enfermedad biliar en individuos con diabetes y obesidad: estudio de cohortes de base poblacional ajustadas por puntajes de propensión]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabanillas]]></surname>
<given-names><![CDATA[Celia Robles]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[Isabel Hurtado]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Sempere]]></surname>
<given-names><![CDATA[Aníbal]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llopis-Cardona]]></surname>
<given-names><![CDATA[Fran]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Sáez]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Bernal]]></surname>
<given-names><![CDATA[Clara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sanfélix-Gimeno]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO) Health Services Research and Pharmacoepidemiology Unit ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Spanish Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS)  ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>39</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0213-91112025000101401&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0213-91112025000101401&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0213-91112025000101401&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Objective: To evaluate the risk of acute pancreatitis and biliary disease in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA).  Method: Population-based, propensity-weighted, new user, active comparator design study including patients with diabetes and obesity initiating treatment with GLP-1 RA or the comparator group sodium-glucose cotransporter 2 inhibitors (SGLT-2i) in the region of Valencia from 2015 to 2021.  Results: In adjusted, per protocol main analysis, no risk differences were found for acute pancreatitis (HR: 0.56; 95%CI: 0.17-1.91) nor for biliary disease (HR: 1.12; IC95%: 0.79, 1.58). Secondary analyses yielded similar results.  Conclusions: Despite we did not observe increased risk of gastrointestinal events in GLP-1 RA vs SGLT-2i patients, adherence to approved indications and close monitoring of potential adverse events are warranted to ensure patient safety.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo: Evaluar el riesgo de pancreatitis aguda y enfermedad biliar en pacientes tratados con agonistas del receptor del péptido similar al glucagón tipo 1 (aGLP-1).  Método: Estudio de base poblacional, ajustado por índices de propensión, de nuevos usuarios y con comparador activo, incluyendo pacientes con diabetes y obesidad que iniciaron tratamiento con aGLP-1 o con un comparador inhibidor del cotransportador de sodio-glucosa 2 (iSGLT-2) en la Comunidad Valenciana, desde 2015 hasta 2021.  Resultados: En el análisis principal, ajustado por protocolo, no se encontraron diferencias en el riesgo de pancreatitis aguda (HR: 0,56; IC95%: 0,17-1,91) y de enfermedad biliar (HR: 1,12; IC95%: 0,79-158). Los análisis secundarios arrojaron resultados similares.  Conclusiones: A pesar de que no se observó un mayor riesgo de eventos gastrointestinales en los pacientes con aGLP-1 frente a los tratados con iSGLT-2, es necesario asegurar el cumplimiento de las indicaciones aprobadas, así como una estrecha monitorización de posibles eventos adversos para garantizar la seguridad de los pacientes.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Cohort study]]></kwd>
<kwd lng="en"><![CDATA[Comparative study]]></kwd>
<kwd lng="en"><![CDATA[Diabetes mellitus type 2]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Glucagon-like peptide-1 receptor agonists]]></kwd>
<kwd lng="en"><![CDATA[Sodium-glucose cotransporter 2 inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Gallbladder diseases]]></kwd>
<kwd lng="en"><![CDATA[Pancreatitis]]></kwd>
<kwd lng="en"><![CDATA[Pharmacoepidemiology]]></kwd>
<kwd lng="es"><![CDATA[Estudio de cohortes]]></kwd>
<kwd lng="es"><![CDATA[Estudio comparativo]]></kwd>
<kwd lng="es"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Obesidad]]></kwd>
<kwd lng="es"><![CDATA[Agonistas del receptor del péptido similar al glucagón tipo 1]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores del cotransportador de sodio-glucosa tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades de la vesícula biliar]]></kwd>
<kwd lng="es"><![CDATA[Pancreatitis]]></kwd>
<kwd lng="es"><![CDATA[Farmacoepidemiología]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Greenway]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Khalid]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[STEP 8 Investigators Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2022</year>
<volume>327</volume>
<page-range>138-50</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gudin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ladhari]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Robin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incretin-based drugs and intestinal obstruction: a pharmacovigilance study]]></article-title>
<source><![CDATA[Therapie]]></source>
<year>2020</year>
<volume>75</volume>
<page-range>641-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalas]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Galura]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[McCallum]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication-induced gastroparesis: a case report]]></article-title>
<source><![CDATA[J Investig Med High Impact Case Rep]]></source>
<year>2021</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2013</year>
<volume>173</volume>
<page-range>534-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sodhi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rezaeianzadeh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kezouh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2023</year>
<volume>330</volume>
<page-range>1795-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Sempere]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Orrico-Sánchez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Quiles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Data resource profile: the Valencia Health System Integrated Database (VID)]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>2020</year>
<volume>49</volume>
<page-range>740-1</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples]]></article-title>
<source><![CDATA[Stat Med]]></source>
<year>2009</year>
<volume>28</volume>
<page-range>3083-107</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ping]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2022</year>
<volume>182</volume>
<page-range>513-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
